Carboxylesterase‐responsive motifs are introduced in the vehicle, endowing the delivery vehicle enzymatic responsiveness in hepatocyte and disrupt the target PCSK9 gene and achieve a potent therapeutic efficacy for hyperlipidemia. The gene discussed is PCSK9; the disease is hyperlipidemia.